Biopsy Device Market is Set to Witness Expansion at a CAGR

NEWARK, Del., Dec. 28, 2022 (GLOBE NEWSWIRE) — The biopsy device market size is predicted to be worth US$ 2.1 billion in 2023, rising to US$ 3.3 billion by 2033. The market for biopsy device is expected to grow at a significant CAGR of 4.9 % during the forecast period.

The demand for biopsy devices is greatly increased by the industry’s requirement for minimally invasive biopsy methods. It is anticipated that a number of technologies and products, including vacuum-assisted devices, needle-based biopsy guns, and biopsy guiding systems, experience substantial growth over the course of the projected period.

Due to growing public awareness of breast cancer treatment and diagnostics, the biopsy device industry is expected to increase significantly over the coming years. Programs for the early identification of breast cancer are available in many nations.

Request for In-depth Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1192

The World Health Organization (WHO) estimates that cancer is responsible for roughly 10 million deaths in 2020. Breast cancer, lung cancer, and leukemia are three malignancies whose prevalence is increasing, which is favorably affecting the demand prognosis for biopsy devices.

Throughout the projection period, a number of efforts made by governments and healthcare organizations addressing cancer treatment and diagnostics are projected to further boost market expansion. Similar to this, rising healthcare costs and significant research and development (R&D) efforts are favorably impacting the industry.

Liquid samples aid in real-time disease progression detection, outcome prediction, medication switching when necessary, and perhaps prolong patient survival. Therefore, the liquid biopsy process is projected to pose a serious threat to the development of the market growth for biopsy devices over the next ten years.

Key Takeaways from the Biopsy Device Market

  • The US biopsy device market is expected to expand at a CAGR of 4.9% over the anticipated time frame. By 2033, it is anticipated that sales of biopsy devices in the US are likely to surpass US$ 150 million.
  • Sales of biopsy devices increased at a 6.2% CAGR between 2017 and 2022, citing FMI’s study.
  • The market for biopsy devices in the UK is anticipated to grow at the greatest rate, 3.9% CAGR. By 2033, it is expected that the UK market would have contributed more than US$ 159 million in revenue.
  • Germany’s biopsy device sector is estimated to exceed US$ 236 million by 2033.
  • Between 2023 and 2033, sales of biopsy devices are likely to increase in China and India at 4.7% and 3.9% CAGR, respectively.
  • Needles segment dominates the biopsy device market with the CAGR of 5.2% by 2033.

Competitive Landscape

Companies are engaging in strategic mergers and acquisitions to expand their portfolio of biopsy devices, and they are concentrating on distribution partnerships to address concerns with product accessibility across different geographies.
In a market for biopsy devices that is incredibly competitive, there are many startup companies. To meet the rising demand for biopsy devices from medical facilities, these businesses are launching cutting-edge goods and services in the market.

Click to Talk with Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-1192

Recent Developments

  • A well-known manufacturer of medical devices used in interventional radiology and interventional oncology procedures, IZI Medical Products LLC (“IZI”), introduced the Quick-Core Auto Biopsy System (“Quick-Core Auto”) for soft tissue biopsy in March 2021 .
  • NeoDynamics AB, a MedTech company focused on enhancing breast cancer diagnosis and care, partnered with the Buckinghamshire Healthcare NHS Trust in London in November 2020 to provide its NeoNavia pulse biopsy technology.

Key Segments

By Product Type:

  • Guidance System
  • Needles
  • Guns
  • Reagents and Kits
  • Others

By Application:

  • Medical Diagnosis
  • Scientific Research

By End Use:

  • Hospital
  • Specialized Oncology Centers
  • Diagnostic Centers
  • Research Institutes

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • THERE
  • Japan
  • MoE

Request Customized Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-1192

Table of Contents

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

Browse Full Report@ https://www.futuremarketinsights.com/reports/biopsy-device-market

Explore FMI’s Extensive Coverage on Healthcare Domain:

Pancreatic Cancer Market Share : The global pancreatic cancer market will be valued at around US$ 2,125.57 Million in 2023. Market of Pancreatic Cancer are projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033.

Non-Small Cell Lung Carcinoma (NSCLC) Market Size : The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of US$ 8.25 Billion in 2023 and is expected to accumulate a market value of US$ 21.40 Billion by registering a CAGR of 10% in the forecast period 2023-2033

Primary Sclerosing Cholangitis (PSC) Market Forecast : The global Primary Sclerosing Cholangitis (PSC) market size is expected to be valued at US$ 151.07 Million in 2023.

Rare NGR1 Fusion Market Demand : The global rare NGR1 fusion market is expected to surpass an impressive valuation of US$ 9.49 Billion in 2023 and is projected to reach US$ 20 Billion by 2033, with a CAGR of 7.73%.

Amyotrophic Lateral Sclerosis Market Growth : The global Amyotrophic Lateral Sclerosis market is expected to garner a market value of US$ 743.90 Million in 2023 and is expected to accumulate a market value of US$ 1332.22 Million by registering a CAGR of 6% in the forecast period 2023-2033.

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter | Blogs | to YouTube
For Sales Enquiries: sales@futuremarketinsights.com

.

Leave a Comment

Your email address will not be published. Required fields are marked *

%d bloggers like this: